S&P 500   3,894.78 (+2.19%)
DOW   31,616.28 (+2.21%)
QQQ   320.76 (+2.11%)
AAPL   124.89 (+2.99%)
MSFT   236.15 (+1.62%)
FB   261.02 (+1.32%)
GOOGL   2,047.00 (+1.24%)
TSLA   707.15 (+4.69%)
AMZN   3,105.70 (+0.41%)
NVDA   547.24 (-0.24%)
BABA   239.76 (+0.84%)
CGC   34.60 (+5.65%)
GE   13.22 (+5.42%)
MU   93.91 (+2.60%)
NIO   49.59 (+8.32%)
AMD   85.44 (+1.10%)
T   28.34 (+1.61%)
F   11.99 (+2.48%)
ACB   11.22 (+6.65%)
DIS   196.76 (+4.08%)
BA   226.14 (+6.66%)
NFLX   548.94 (+1.87%)
BAC   35.70 (+2.85%)
S&P 500   3,894.78 (+2.19%)
DOW   31,616.28 (+2.21%)
QQQ   320.76 (+2.11%)
AAPL   124.89 (+2.99%)
MSFT   236.15 (+1.62%)
FB   261.02 (+1.32%)
GOOGL   2,047.00 (+1.24%)
TSLA   707.15 (+4.69%)
AMZN   3,105.70 (+0.41%)
NVDA   547.24 (-0.24%)
BABA   239.76 (+0.84%)
CGC   34.60 (+5.65%)
GE   13.22 (+5.42%)
MU   93.91 (+2.60%)
NIO   49.59 (+8.32%)
AMD   85.44 (+1.10%)
T   28.34 (+1.61%)
F   11.99 (+2.48%)
ACB   11.22 (+6.65%)
DIS   196.76 (+4.08%)
BA   226.14 (+6.66%)
NFLX   548.94 (+1.87%)
BAC   35.70 (+2.85%)
S&P 500   3,894.78 (+2.19%)
DOW   31,616.28 (+2.21%)
QQQ   320.76 (+2.11%)
AAPL   124.89 (+2.99%)
MSFT   236.15 (+1.62%)
FB   261.02 (+1.32%)
GOOGL   2,047.00 (+1.24%)
TSLA   707.15 (+4.69%)
AMZN   3,105.70 (+0.41%)
NVDA   547.24 (-0.24%)
BABA   239.76 (+0.84%)
CGC   34.60 (+5.65%)
GE   13.22 (+5.42%)
MU   93.91 (+2.60%)
NIO   49.59 (+8.32%)
AMD   85.44 (+1.10%)
T   28.34 (+1.61%)
F   11.99 (+2.48%)
ACB   11.22 (+6.65%)
DIS   196.76 (+4.08%)
BA   226.14 (+6.66%)
NFLX   548.94 (+1.87%)
BAC   35.70 (+2.85%)
S&P 500   3,894.78 (+2.19%)
DOW   31,616.28 (+2.21%)
QQQ   320.76 (+2.11%)
AAPL   124.89 (+2.99%)
MSFT   236.15 (+1.62%)
FB   261.02 (+1.32%)
GOOGL   2,047.00 (+1.24%)
TSLA   707.15 (+4.69%)
AMZN   3,105.70 (+0.41%)
NVDA   547.24 (-0.24%)
BABA   239.76 (+0.84%)
CGC   34.60 (+5.65%)
GE   13.22 (+5.42%)
MU   93.91 (+2.60%)
NIO   49.59 (+8.32%)
AMD   85.44 (+1.10%)
T   28.34 (+1.61%)
F   11.99 (+2.48%)
ACB   11.22 (+6.65%)
DIS   196.76 (+4.08%)
BA   226.14 (+6.66%)
NFLX   548.94 (+1.87%)
BAC   35.70 (+2.85%)
Log in
NASDAQ:ZGNX

Zogenix Stock Forecast, Price & News

$21.32
+0.11 (+0.52 %)
(As of 03/1/2021 10:40 AM ET)
Add
Compare
Today's Range
$21.30
Now: $21.32
$21.76
50-Day Range
$18.26
MA: $20.85
$23.43
52-Week Range
$16.65
Now: $21.32
$32.42
Volume2,750 shs
Average Volume994,229 shs
Market Capitalization$1.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.6
Zogenix, Inc., a pharmaceutical company, develops and commercializes transformative therapies to enhance the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS); and which is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It also developing MT1621, an investigational deoxynucleoside substrate enhancement therapy for the treatment of inherited mitochondrial DNA depletion disorder thymidine kinase 2 deficiency (TK2d). Zogenix, Inc. has collaboration with Tevard Biosciences to advance novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Zogenix logo

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ZGNX
CUSIP98978L10
Phone510-550-8300
Employees141
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.65 million
Book Value$5.54 per share

Profitability

Net Income$-419,500,000.00
Net Margins-8,758.48%

Miscellaneous

Market Cap$1.19 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.69 out of 5 stars

Medical Sector

255th out of 1,962 stocks

Pharmaceutical Preparations Industry

121st out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$21.32
+0.11 (+0.52 %)
(As of 03/1/2021 10:40 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

Is Zogenix a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zogenix stock.
View analyst ratings for Zogenix
or view top-rated stocks.

What stocks does MarketBeat like better than Zogenix?

Wall Street analysts have given Zogenix a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zogenix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Zogenix's next earnings date?

Zogenix is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Zogenix
.

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) posted its earnings results on Thursday, February, 25th. The company reported ($1.26) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.05) by $0.21. Zogenix had a negative trailing twelve-month return on equity of 53.91% and a negative net margin of 8,758.48%.
View Zogenix's earnings history
.

How has Zogenix's stock been impacted by COVID-19?

Zogenix's stock was trading at $22.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZGNX stock has decreased by 5.2% and is now trading at $21.52.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ZGNX?

7 brokerages have issued 1-year price targets for Zogenix's stock. Their forecasts range from $27.00 to $65.00. On average, they anticipate Zogenix's stock price to reach $52.00 in the next year. This suggests a possible upside of 141.6% from the stock's current price.
View analysts' price targets for Zogenix
or view top-rated stocks among Wall Street analysts.

Who are Zogenix's key executives?

Zogenix's management team includes the following people:
  • Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 62, Pay $867.95k)
  • Mr. Michael P. Smith, Exec. VP, CFO & Treasurer (Age 53, Pay $573.34k)
  • Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 59, Pay $582.08k)
  • Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 57, Pay $568.5k)
  • Mr. Ashish M. Sagrolikar, Exec. VP & Chief Commercial Officer (Age 54, Pay $541.24k)
  • Mr. Jeff D. Durflinger, VP of Technical Operations & Product Supply (Age 60)
  • Ms. Shawnte M. Mitchell, Exec. VP, Gen. Counsel & Sec. (Age 43)
  • Melinda Baker, Sr. Director of Corp. Communications
  • Mr. Bret E. Megargel, VP of Corp. Devel. (Age 52)
  • Mr. Stephen H. Jenner, VP of Marketing (Age 53)

What is Stephen Farr, Ph.D.'s approval rating as Zogenix's CEO?

7 employees have rated Zogenix CEO Stephen Farr, Ph.D. on Glassdoor.com. Stephen Farr, Ph.D. has an approval rating of 85% among Zogenix's employees.

Who are some of Zogenix's key competitors?

What other stocks do shareholders of Zogenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals (GWPH), Gilead Sciences (GILD), Vanda Pharmaceuticals (VNDA), AbbVie (ABBV), QUALCOMM (QCOM), Advanced Micro Devices (AMD), (CGC), Sorrento Therapeutics (SRNE), Southwest Airlines (LUV) and Micron Technology (MU).

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

Who are Zogenix's major shareholders?

Zogenix's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.40%), Morgan Stanley (5.69%), Federated Hermes Inc. (4.09%), Bank of New York Mellon Corp (3.35%), Janus Henderson Group PLC (3.16%) and Candriam Luxembourg S.C.A. (1.55%). Company insiders that own Zogenix stock include Ashish M Sagrolikar, Cam L Garner, Gail M Farfel, James B Breitmeyer, Mark C Wiggins, Michael P Smith, Renee P Tannenbaum, Roger Hawley and Stephen J Farr.
View institutional ownership trends for Zogenix
.

Which major investors are selling Zogenix stock?

ZGNX stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Nuveen Asset Management LLC, Federated Hermes Inc., Candriam Luxembourg S.C.A., Squarepoint Ops LLC, Granite Point Capital Management L.P., Duality Advisers LP, and First Midwest Bank Trust Division.
View insider buying and selling activity for Zogenix
or view top insider-selling stocks.

Which major investors are buying Zogenix stock?

ZGNX stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Assenagon Asset Management S.A., Hood River Capital Management LLC, Scopia Capital Management LP, Renaissance Technologies LLC, GW&K Investment Management LLC, BlackRock Inc., and SG Americas Securities LLC. Company insiders that have bought Zogenix stock in the last two years include Ashish M Sagrolikar, Cam L Garner, and Mark C Wiggins.
View insider buying and selling activity for Zogenix
or or view top insider-buying stocks.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $21.52.

How much money does Zogenix make?

Zogenix has a market capitalization of $1.20 billion and generates $3.65 million in revenue each year. The company earns $-419,500,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis.

How many employees does Zogenix have?

Zogenix employs 141 workers across the globe.

What is Zogenix's official website?

The official website for Zogenix is www.zogenix.com.

Where are Zogenix's headquarters?

Zogenix is headquartered at 5959 Horton Street Suite 500, EMERYVILLE CA, 94608.

How can I contact Zogenix?

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.